Skip to main content

Market Overview

The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Here's a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech stocks hitting 52-week highs on Feb. 5)

  • Amphastar Pharmaceuticals Inc (NASDAQ: AMPH)
  • Array Biopharma Inc (NASDAQ: ARRY) (reported a narrower-than-expected loss for Q2)
  • Axsome Therapeutics Inc (NASDAQ: AXSM)
  • Osiris Therapeutics, Inc. (NASDAQ: OSIR)
  • XBiotech Inc (NASDAQ: XBIT)

Down In The Dumps

(Biotech stocks hitting 52-week lows on Feb. 5)

  • BioNano Genomics Inc (NASDAQ: BNGO)
  • CELLECT BIOTECH/S ADR (NASDAQ: APOP) (began collaboration with Washington University aimed at determining the safety and tolerability in a Phase 1/2 study using ApoGraft for bone marrow transplantations)

Stock In Focus

Paratek Commercially Launches its Recently Approved Antibiotic In The U.S.

Paratek Pharmaceuticals Inc (NASDAQ: PRTK) announced the U.S. commercial launch of its recently approved Nuzyra for treating community-acquired pneumonia and acute skin and skin structure infections.

"We have created a solid foundation from which to launch NUZYRA including beginning to secure institutional access and building a world-class antibiotic sales force whose primary focus during this first year of launch will be directed towards physicians with a history of early adoption," said Michael Bigham, CEO of Paratek.

The stock rallied 7.73 percent to $7.25 in after-hours trading.

Vanda Sues FDA

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) said it has filed a complaint against the FDA for lifting the partial clinical hold the agency had imposed on the company, prohibiting it from studying tradipitant, a promising new drug, in humans more than 12 weeks without conducting unnecessary and unethical animal studies.

The stock fell 4.23 percent to $24 in after-hours trading.


Catabasis Pharmaceuticals Inc (NASDAQ: CATB) intends to offer its common stock in an underwritten public offering. The company intends to use the net proceeds from the offering for clinical trials and other R&D activities, among others.

The stock slumped 15.37 percent to $5.12 in after-hours trading.

Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) priced its underwritten public offering of 3.75 million shares at $8 per share. The company expects gross proceeds of $60 million from the offering. The offering is expected to close on or about Feb. 8.

The stock declined 6.79 percent to $8.78 in after-hours trading.

See Also: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates


Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported Q4 total revenues of $870.11 million, up from $651.63 million in the year-ago quarter. The non-GAAP EPS more than doubled from 61 cents to $1.30. Analysts, on average, estimated earnings of $1.06 per share on revenues of $819.12 million.

For FY19, the company expects total CF product revenues of $3.45 billion to $3.55 billion. Analysts expect total revenues of $3.55 billion.

The stock rose 3.02 percent to $192.50 in after-hours trading.

Myriad Genetics, Inc. (NASDAQ: MYGN) reported fiscal-year 2018 second-quarter revenues of $216.8 million, up 15 percent year-over-year, and adjusted EPS came in at 38 cents, up 6 percent. The EPS trailed expectations but revenues were in line.

For Q3, the company expects non-GAAP EPS of 42-44 cents on revenues of $216 million to $218 million. The company guided fiscal year 2019 non-GAAP EPS to $1.70-$1.75 on revenues of $855 million to $865 million.

The stock moved down 3.66 percent to $26.85 in after-hours trading.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q4 revenues of $131.5 million compared to $94.5 million in the year-ago quarter. The EPS for the quarter rose from 7 cents to 19 cents. The results exceeded estimates.

For 2019, the company expects revenue milestones under the AbbVie Inc (NYSE: ABBV) agreement to be $20 million, contingent on the FDA accepting the NDA submission of elagolix for uterine fibroids. SG&A and R&D expenses are estimated at $550 million to $600 million.

The stock gained 0.63 percent to $88.25 in after-hours trading.

On The Radar

Clinical Trial Results

Avrobio Inc (NASDAQ: AVRO) is scheduled to release update on Phase 1 study and two-year data for first patient treated with Fabry disease candidate AVR-RD-01 at the WORLDSymposium.

Abeona Therapeutics Inc (NASDAQ: ABEO) will release Phase 1/2 safety and tolerability data for ABO-102, its treatment candidate for Sanfilippo syndrome type A, at the WORLDSymposium.


Boston Scientific Corporation (NYSE: BSX) Q4 Adj. EPS $0.39 Beats $0.37 Estimate, Sales $2.56B Inline
Eli Lilly And Co (NYSE: LLY) Q4 EPS $1.33 Misses $1.34 Est, Sales $6.438B Beat $6.28B Est.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 Adj. EPS $6.84 Beats $5.72 Estimate, Sales $1.93B Beat $1.71B Estimate
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) (after the close)
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the close)


Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Offerings FDA Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at